

Tayside Oral Hypoglycaemic Drug Prescribing Guidance

September 2006

The following guidance has been agreed by the Tayside Diabetes MCN as an appropriate and evidence-based approach to the prescribing of oral hypoglycaemic drugs for patients with diabetes in Tayside.

For Patients with BMI of 27+ (or 22+ in non-Caucasians)

1. Monotherapy - Metformin (or Glitazone if c/i to Metformin)
2. Add Glitazone (or Sulphonylurea if c/i to Glitazone)
3. Add Sulphonylurea (Triple Therapy)
4. Change to Insulin (usually maintaining Metformin)

For Patients with BMI of less than 27 (or less than 22 in non-Caucasians)

1. Monotherapy - Sulphonylurea or Metformin (or Glitazone if c/i to both Metformin and Sulphonylurea)
2. Add Metformin or Sulphonylurea
3. Change to Insulin (usually maintaining Metformin)
4. Triple Oral Therapy (metformin sulphonylurea and glitazone) can be considered in patients for whom Insulin therapy is not practicable.